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RA diagnoses were most prevalent in the Marmara region (38%), followed by Ae-
gean (20%), Central Anatolia (21%), and Mediterranean (15%). Nearly 40% of RA
patients had at least one cardiovascular, diabetic, respiratory or allergy comorbid
condition prior to diagnosis. 5% of patients were hospitalized and 42% had at least
one outpatient visit during the pre-index period. Most patients were prescribed
non-COX inhibitors (78%) and immunosuppressants (71%), and 11% of patients
were prescribed disease-modifying anti-rheumatic drugs (DMARDs). Few patients
(1%) had surgery prior to diagnosis. The total annual cost (a2,386) was comprised of
mainly pharmacy (a1,747), followed by outpatient (a360), and inpatient costs (a252),
and an average copay of 27a. Prior comorbid conditions including diabetes, respi-
ratory disease as well as hospitalization, glucocorticoid and DMARD use signifi-
cantly contributed to annual health care costs, unlike gender and age.
CONCLUSIONS: Annual costs of RA patients are significantly lower in Turkey rel-
ative to other countries in Europe, yet, pharmaceutical expenditures cover a sig-
nificant portion of the overall cost. Comparative effectiveness studies are needed to
further decrease pharmaceutical expenditures for RA treatment.
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OBJECTIVES: To determine indirect costs of rheumatoid arthritis (RA) due to work
loss, RA-related consultations, additional investments and caregivers in patients
who utilized public health care facility services in Turkey. Association between
indirect cost and disease activity scores such as Global Disease Activity (GDA),
EuroQoL health status (EQ-5D), visual analog scale (VAS), Health Assessment Ques-
tionnaire (HAQ) and the Routine assessment of patient index data (RAPID-3) were
also analyzed. METHODS: This cross-sectional study was performed in 10 univer-
sity rheumatology centers. Eligible patients were age18, diagnosed with RA for at
least 12 months according to the American College of Rheumatology (ACR) 1987
criteria. We assessed relevant indirect cost variables, activities associated with
indirect costs, and actual costs. Multivariate regression determined variables as-
sociated with higher indirect costs. Pearson correlation examined the association
between indirect costs and disease activity scores. RESULTS:A total of 698 patients
(82% female; mean age: 51.2  13.17 standard deviation [SD]) were questioned
regarding indirect RA costs. 14% were employees, of which 62% had employer
permission to miss work (average 27 days annually) due to RA, costing patients an
average €480 annually due to workday loss. 5.4% of patients had other RA-related
consultations not covered by insurance (acupuncture, homeopathic, other), bring-
ing their average annual burden to €1,600. 6.5% of RA patients incurred additional
RA-related costs (e.g. need for new car, apartment, special equipment), spending
an additional €1,640 in 1 year. 13.7% of patients required caregivers. The average
annual out-of-pocket amount paid to caregivers was €624. Multivariate regression
showed that age and gender were not significantly related to indirect costs. Pa-
tients needing caregivers reported significantly higher GDA, VAS, HAQ, RAPID-3
and lower EQ-5D scores. CONCLUSIONS: Indirect RA-related costs in Turkey are
significant. Comparative effectiveness studies on RA treatment should include di-
rect and indirect costs.
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OBJECTIVES: To estimate risk-adjusted health care costs and identify associated
risk factors for ankylosing spondylitis (AS) expenditures in Turkey using real-world
data. METHODS: This study used research-identified data from a system that pro-
cesses claims for all Turkish health insurance funds. Incident cases of adult AS
patients with two AS visits at least 60 days apart, identified between June 1, 2010
and December 31, 2010, were required to have no AS diagnosis before June 1, 2010,
with at least 1 year of continuous enrollment for the baseline and follow-up years.
Pharmacy, outpatient and inpatient claims were compiled over the study period for
the selected patients. RESULTS: Among 603 patients (mean age: 38.74; female:
44%), 58% were age 18-39, 39% were 40-64 years and 3% were age 65 or older. AS
diagnosis was most prevalent in the Marmara region (49%), followed by Central
Anatolia (22%), Aegean (13%), and Mediterranean (7%). Nearly 25% of AS patients
had at least one cardiovascular, diabetic, respiratory, allergy, Crohn’s disease and
rheumatoid arthritis comorbid condition prior to diagnosis. Most patients were
prescribed non-COX inhibitors (67%) and 7% of patients were prescribed disease-
modifying anti-rheumatic drugs (DMARDs). The total annual cost (a2,254) was com-
prised of mainly pharmacy (a1,738), followed by outpatient (a331), and inpatient
costs (a162), and an average copay of a23. Prior comorbid conditions including dia-
betes, respiratory disease as well as hospitalization, glucocorticoid and DMARD use
significantly contributed to annual health care costs, unlike gender and age.
CONCLUSIONS: Annual costs of AS patients are significantly lower in Turkey rela-
tive to other countries in Europe, yet, pharmaceutical expenditures cover a signif-
icant portion of the overall cost. Comparative effectiveness studies are needed to
further decrease pharmaceutical expenditures for AS treatment.
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OBJECTIVES: International pharmacoeconomic studies suggest Health Assess-
ment Questionnaire (HAQ) as an important predictor of evaluation both direct and
productivity costs of rheumatoid arthritis (RA). Costs are supposed to increase with
increasing HAQ value. Therefore, we calculated direct (from health insurances
perspective) and productivity costs for five groups of patients according to their
HAQ (0.6, 0.6-1.1, 1.1-1.6, 1.6-2.1, 2.1) to confirm this assumption also in the
Slovak Republic. METHODS: This calculation was based on a retrospective cross-
sectional study. We included 119 patients with rheumatoid arthritis, aged 18-84
years either at working status, part-time disabled or full-time disabled. We used
prevalence-based cost-of-illness method type bottom-up, retrospectively review-
ing individual patient’s medical record. For calculation of productivity costs we
excluded patients older than 63 years of age (retirement pensioners). We used
friction costs approach (FCA) with defined friction period of 130 workdays, based on
patients’ absenteeism due to RA. Productivity of part-time-disabled and full-time
disabled patients were assumed to be deteriorated by 50% and 70%, respectively,
based on the Slovak law on pension insurance. The height of average monthly
income in year 2010, €769 was used as denominator. Costs were expressed as mean
value per one patient with RA in each of the HAQ-group. RESULTS: Average pa-
tients= age was 49.5 years; average time from diagnosis was 12.3 years with mean
HAQ score 1.4 and mean DAS28 5.0. Mean annual medical direct costs, for each
HAQ-group, were €516, €468, €943, €1676, and €1466, respectively. Mean annual
indirect costs associated with productivity loss were €224, €1600, €1847, €2109, and
€2030, respectively. CONCLUSIONS: Direct and productivity costs for patients with
rheumatoid arthritis are closely related to the height of HAQ score. Total (direct and
productivity) annual mean costs were €2576.
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OBJECTIVES: To examine the resource utilization and direct costs of care associ-
ated with use of biologic agents therapy among prevalent rheumatoid arthritis (RA)
patients based on retrospective health care claims data. The database (EGB) is a
1/97 representative sample of the national claim database covering the whole
French population. METHODS: RA patients were identified as adults (age 18)
benefiting from full coverage (ALD eligibility criteria) for RA (ICD-10 M05-06) on
January 1, 2009 and still alive on December 31st, 2010. Biologics treated patients
(BTP) were defined as RA patients with 1 claim for biologics in 2010. All health
expenses were assessed from the payer’s perspective. A log-linear generalised
model was used to adjust the costs in comparing BTP versus patients not treated by
biologics (BNP). RESULTS: A total of 1,234 RA patients were identified of whom 199
(16.0%) were treated with biologics (BTP) including TNF inhibitors in 85% of cases. In
comparing patients not treated by biologics (BNP) versus BTP, the proportion of
male patients (24.1% versus 24.1% p0.99) nor the time since registration for RA
coverage (8.5 versus 9.0 years p0.33) were significantly different but BTP patients
were significantly younger 55.2 years  12.9 versus 64.1 years  14.5 (p0.0001).
The unadjusted per capita annual expenses of BTP were three times higher than in
BNP (15,581 € versus 4,892 € - p0.0001). Drug costs were respectively 8,477 € (54.4%
of total) versus 1,151€ (23.5% of total) (p 0.0001) and in-patient care 4,878 € (31.3%
of total) versus 1,696 € (34.7% of total) (p 0.0001). After adjustment for age, the
mean annual extra cost of patients on biologics was in the range 11,000 € - 12,000 €.
CONCLUSIONS: When compared to similar data prior to the era of biologics, the
structure of medical expenses in RA patients has shifted from in-patient care to-
wards drugs.
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OBJECTIVES: To examine the resource utilization and direct costs of care of prev-
alent rheumatoid arthritis (RA) patients using retrospective health care claims
data. METHODS: The EGB is a national representative 1/97 sample of individuals
covered by the French Health Insurance. Individuals presenting with RA (ICD-10 codes:
M05-06) can be identified in the database because they benefit from a full coverage. All
items of health care utilization and associated costs were assessed from the Health
Insurance perspective for 2010. The economic burden of RA was estimated by com-
paring medical expenses in the RA adult (18 years) population to a control group
matched on sex and age and using non parametric Mann-Whitney tests. RESULTS:
A total number of 1,296 RA patients were identified, i.e. a crude prevalence rate of
3.47/1000. The mean age was 63.3 years ( 14.8) and the sex ratio H/F was 0.33. A
proportion of 39.4% of patients benefitted from additional full coverage for other
co-morbibities, severe Hypertension (7.8%), NIDD (6.1%), Ischemic Heart Disease
(3%), Depression (1.9%) being the most frequent. Annual medical costs of the RA
population were 2 times higher than control (6,607 € versus 3,248 € p0.0001). The
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